Literature DB >> 8230123

Synthesis and LTB4 receptor antagonist activities of the naturally occurring LTB4 receptor antagonist Leucettamine A and related analogues.

J C Boehm1, J G Gleason, I Pendrak, H M Sarau, D B Schmidt, J J Foley, W D Kingsbury.   

Abstract

The isolation and structure determination of the naturally occurring LTB4 receptor antagonist Leucettamine A (1) was recently reported. Herein we describe the synthesis of this natural product, the preparation of several analogues, and their effectiveness as antagonists of [3H]LTB4 binding to intact human U-937 cells. Total synthesis of Leucettamine A (1) is achieved by a convergent route which takes advantage of the elements of symmetry within the molecule. Syntheses of analogues of 1, which lacked the same degree of symmetry, are achieved by a different approach starting from alpha-amino acids. The natural product 1 inhibits [3H]LTB4 binding to its receptors on intact human U-937 cells with a Ki = 3.5 +/- 0.8 microM and is devoid of measurable agonist activity at the concentrations tested. 2-Amino imidazole analogues of 1 lacking the dioxolane groups were prepared. Generally these are significantly less potent than 1. However, one (26), designed on the basis of a putative structural overlay with LTB4, demonstrated potency comparable to that of the natural product (Ki = 2.4 +/- 0.2 microM).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230123     DOI: 10.1021/jm00074a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  1 in total

Review 1.  Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases.

Authors:  Nadège Loaëc; Eletta Attanasio; Benoît Villiers; Emilie Durieu; Tania Tahtouh; Morgane Cam; Rohan A Davis; Aline Alencar; Mélanie Roué; Marie-Lise Bourguet-Kondracki; Peter Proksch; Emmanuelle Limanton; Solène Guiheneuf; François Carreaux; Jean-Pierre Bazureau; Michelle Klautau; Laurent Meijer
Journal:  Mar Drugs       Date:  2017-10-17       Impact factor: 5.118

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.